| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TP53 |
| Uniprot No | P04637 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-393aa |
| 氨基酸序列 | MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD |
| 预测分子量 | 45.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TP53重组蛋白的参考文献摘要：
---
1. **标题**：*Structural Basis of DNA Binding by p53*
**作者**：Cho Y. et al. (1994)
**摘要**：通过X射线晶体学解析了重组人p53蛋白核心结构域与DNA结合的分子机制，揭示了p53如何特异性识别靶基因的DNA序列，为研究癌症相关突变对DNA结合能力的影响提供结构基础。
---
2. **标题**：*Structural Evolution of p53. p63. and p73*
**作者**：Joerger A.C., Fersht A.R. (2008)
**摘要**：比较了重组表达的p53家族蛋白(p53/p63/p73)的结构与功能差异，重点分析了p53核心结构域的热稳定性及突变导致的功能丧失机制，为设计恢复突变p53活性的药物提供依据。
---
3. **标题**：*Restoration of the Tumor Suppressor Function to Mutant p53 by a Low-Molecular-Weight Compound*
**作者**：Bykov V.J. et al. (2002)
**摘要**：利用重组表达的突变型p53蛋白进行高通量筛选，发现小分子化合物PRIMA-1可恢复突变p53的构象及转录活性，为靶向p53突变的癌症治疗策略奠定实验基础。
---
**备注**：以上文献发表于不同时期，涵盖结构解析、功能机制及药物开发方向，具体发表期刊可通过PubMed或Google Scholar查询标题获取。如需更近期研究，可补充关键词如"recombinant p53 protein cancer therapy 2023"进一步检索。
**Background of TP53 Recombinant Protein**
The TP53 gene, located on chromosome 17p13.1. encodes the p53 protein, a critical tumor suppressor involved in maintaining genomic stability. Often termed the "guardian of the genome," p53 functions as a transcription factor that regulates cell cycle arrest, DNA repair, apoptosis, and senescence in response to cellular stress, such as DNA damage, hypoxia, or oncogenic activation. Structurally, p53 contains distinct domains: an N-terminal transactivation domain, a central DNA-binding domain (DBD), a tetramerization domain, and a C-terminal regulatory domain. Mutations in TP53 are observed in over 50% of human cancers, typically disrupting its DNA-binding capacity and impairing tumor-suppressive functions.
Recombinant TP53 protein is engineered in vitro using expression systems (e.g., *E. coli*, mammalian cells*) to produce functional or mutant forms of p53 for research and therapeutic applications. This protein retains key biochemical properties, enabling studies on p53-DNA interactions, post-translational modifications (e.g., phosphorylation, acetylation), and interactions with regulators like MDM2. which targets p53 for degradation. Recombinant p53 is vital for elucidating mechanisms of carcinogenesis, drug resistance, and mutant p53 gain-of-function effects.
In drug discovery, TP53 recombinant protein aids in screening compounds that restore wild-type p53 activity or disrupt oncogenic mutant p53. It also supports gene therapy strategies, such as delivering functional TP53 via viral vectors. Despite challenges—including p53's complex regulation and mutation heterogeneity—recombinant p53 remains a cornerstone in cancer biology, offering insights into personalized therapies targeting TP53 pathways.
×
